Brodin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brodin

Quick Facts

Property Description
Active Ingredient Levofloxacin (the S-enantiomer of Ofloxacin)
Pharmaceutical Forms Tablets, Solution for Infusion, Ophthalmic Solution
Pharmacological Class Antibiotic; Fluoroquinolone class
General Purpose Resolution of systemic bacterial infections
Origin Synthetic compound

What is Brodin? Defining the Anti-Infective Agent

Brodin is a systemic anti-infective agent defined by its sole active ingredient, Levofloxacin, and is categorized as a prescription-only medicine. Levofloxacin is a synthetic compound, chemically classified as a chiral fluorinated carboxyquinolone. It is the purified S-enantiomer of the drug Ofloxacin. The selection of this specific isomer is utilized in pharmacology for targeted therapeutic activity and a refined drug profile.

This precise chemical structure positions Brodin within the Fluoroquinolone class of antibiotics, distinguishing it from older antibacterial categories. As a broad-spectrum antibacterial agent, Brodin is designed to provide bactericidal action against a wide range of susceptible pathogens. This specialized medicine functions by actively eliminating the bacteria responsible for various systemic illnesses.

Composition, Forms, and General Therapeutic Scope

Brodin's therapeutic function is achieved through its single active ingredient composition, which acts by inhibiting two key bacterial enzymes: DNA gyrase and Topoisomerase IV.

The disruption of these enzymes blocks essential processes such as bacterial DNA replication and transcription. This mechanism is intended to result in the cessation of bacterial growth and the reduction of the bacterial population.

As a versatile anti-infective, Levofloxacin is prepared in multiple pharmaceutical forms for various administration routes. These include the Tablet (for systemic oral delivery), the Solution for Infusion (for systemic intravenous delivery), and the Ophthalmic Solution (for localized topical application). This structural diversity allows for flexibility in treatment where different delivery options are medically required.

What side effects are possible with Brodin?

Possible side effects and safety information

This section outlines the adverse reactions and safety constraints of Brodin (Levofloxacin) as classified in government regulatory documents from agencies such as the EMA and FDA.


Official Adverse Reaction Categories

Classification Examples of Reactions Affected Systems (SOC)
Common (1/100 to <1/10) Nausea, Diarrhea, Headache, Insomnia, Dizziness, Increased liver enzymes Gastrointestinal, Nervous System, Hepatobiliary
Uncommon (1/1,000 to <1/100) Vomiting, Abdominal pain, Tremor, Anxiety, Joint pain (Arthralgia), Rash, Pruritus Gastrointestinal, Nervous System, Psychiatric, Musculoskeletal, Skin
Rare (1/10,000 to <1/1,000) Tendon disorders (Tendinitis), Psychotic reactions (Hallucinations), Seizures, Tachycardia (fast heart rate) Musculoskeletal, Nervous System, Psychiatric, Cardiac

Serious Adverse Reactions (Label-Documented)

Official regulatory labels include prominent warnings for serious and potentially irreversible adverse reactions:

  • Tendonitis and Tendon Rupture: Increased risk of tendon inflammation and rupture (e.g., Achilles tendon), which can occur during or months after treatment. This is a class warning for Fluoroquinolones.
  • Peripheral Neuropathy: Nerve damage symptoms, such as burning, pain, tingling, or numbness, that may become permanent.
  • Aortic Dissection/Aneurysm: Rare, serious events involving the rupture or dissection of the main artery (aorta).
  • QT Interval Prolongation: An effect on heart rhythm that can lead to Torsades de pointes, particularly in susceptible patients.
  • Exacerbation of Myasthenia Gravis: Use may worsen muscle weakness in individuals with this pre-existing condition.
  • Clostridioides difficile-associated diarrhea (CDAD): Can range from mild diarrhea to life-threatening colitis.

Population-Specific Safety Constraints

  • Older Adults (Geriatric): Have an increased risk of tendon disorders and are more susceptible to certain cardiovascular and hepatic effects.
  • Pediatric Population: Use is generally not recommended for children or growing adolescents due to the risk of musculoskeletal disorders.
  • Renal Impairment: Dosage adjustments are required for patients with reduced kidney function to prevent drug accumulation.

Connection to the Overall Safety Profile

The official safety profile of Brodin, mandated by regulatory agencies, is structured by classifying side effects by frequency and grouping them by affected organ systems. This framework clearly outlines both common, expected adverse reactions and mandates prominent warnings for rare but serious, potentially irreversible events and conditions that require particular caution, such as a history of tendon disorders or Myasthenia Gravis.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose information for Brodin is based on clinical trials where healthy adult volunteers received single high doses, up to 96 mg/kg. At these elevated exposure levels, the documented adverse reactions were generally similar to those observed at the recommended therapeutic doses.

Emergency Actions and Symptoms

In the event of a suspected or confirmed overdose, the administration of this product must be discontinued immediately, and supportive treatment should be initiated. Although high-dose exposure resulted in generally similar adverse effects to regular use, one serious event of cardiac arrest was reported at the 96 mg/kg dose level in a clinical study.

The core of overdose management, as stated in regulatory documents, requires the prompt initiation of general medical supportive measures. Immediate medical help should be sought to ensure this required supportive care is initiated without delay.

Overdose Presentation Factor Official Regulatory Finding
Documented Presentations Adverse reactions generally similar to recommended doses.
Severe Event Noted Single case of cardiac arrest reported at a high dose (96 mg/kg) exposure.
Required Emergency Action Product administration must be discontinued, and supportive treatment initiated.

Therapeutic Uses of Brodin

Quick Facts: Therapeutic Domains

  • Supports management of cough associated with mucus.
  • Assists with clearing of mucus (phlegm) in the airways.
  • Helps relieve symptoms associated with certain broncho-pulmonary disorders.

Brodin is authorized for use in the symptomatic relief of cough that involves the presence of mucus in the airways. The therapeutic goal of Brodin is to facilitate the removal of thick or sticky secretions from the lungs, windpipe, and nose, which in turn may assist in easing the respiratory effort.

This medication is indicated to help manage symptoms associated with various broncho-pulmonary disorders, such as chronic bronchitis and bronchial asthma, where the accumulation of mucus is a complicating factor. By influencing the characteristics of mucus, Brodin aims to support more comfortable breathing. It is often used to address the symptoms of cough resulting from these conditions, but it is not a cure for the underlying disease.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Brodin (Levofloxacin) is an antibiotic subject to strict regulatory eligibility rules that define who can and cannot use the medicine.

Eligibility Scope Status as per Regulatory Labeling
Populations Contraindicated Must not be used in patients with a history of epilepsy, known hypersensitivity to any quinolone, or prior tendon disorders related to this drug class.
Age-Related Rules Generally contraindicated in children and growing adolescents (under 18 years of age). It is approved in children 6 months of age and older only for the specific life-threatening indications of anthrax and plague.
Organ-Function Limits Use is permitted in renal impairment, but a mandatory dosage adjustment is required based on the patient's creatinine clearance. Hepatic impairment typically does not require a dose adjustment.
High-Risk Comorbidities Use must be avoided in patients with a known history of Myasthenia Gravis or known QT interval prolongation. Caution is required for older adults (over 60) and those taking corticosteroids due to increased tendon risk.
Pregnancy and Lactation Use is not recommended during pregnancy (FDA Category C) or breastfeeding due to potential risks, requiring a benefit-risk assessment.

Eligibility is further restricted for certain uncomplicated infections (e.g., uncomplicated UTI), where Brodin is reserved only for patients with no alternative treatment options.

What should I know about interactions with other medicines?

Brodin Interactions with other medicines and products

The interaction profile for Brodin (Levofloxacin) is defined by officially documented pharmacokinetic and pharmacodynamic constraints, requiring specific restrictions on co-administration with other medicines and substances.

Interaction Classifications

Interaction Type Interacting Agent(s) Regulatory Constraint
Reduced Exposure (Pharmacokinetic) Antacids, Sucralfate, Metal-containing Supplements (e.g., Iron, Zinc) Requires mandatory separation of at least two hours before or two hours after oral Brodin administration.
Increased Exposure (Pharmacokinetic) Probenecid, Cimetidine Documented to reduce Levofloxacin renal clearance, leading to increased systemic exposure.
Pharmacodynamic Reinforcement Systemic Corticosteroids Avoid co-administration due to a documented increase in the risk of tendon rupture or tendinitis.
Pharmacodynamic Reinforcement Other QT-prolonging drugs Avoid co-administration due to additive risk of cardiac effects, including the potential for ventricular arrhythmia.

Official Interaction Statements

The regulatory documents note that concurrent use with NSAIDs may increase the risk of CNS stimulation or seizures. Co-administration with Warfarin is documented to potentially enhance its effect; therefore, coagulation tests (INR/PT) must be closely monitored. Antidiabetic agents also require careful monitoring, as concurrent use may lead to disturbances in blood glucose levels. The risk of the corticosteroid-induced tendon rupture interaction is explicitly noted to be increased in elderly patients and those with renal impairment.

Mechanism of Action

How Brodin Works at the Cellular Level

Brodin functions as a covalent modulator that selectively binds to two key transcription factors: NF-kappaB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) and Keap1. This interaction initiates a dual signaling cascade within the cells. By binding to NF-kappaB, Brodin inhibits the transcription of pro-inflammatory genes, resulting in a decrease in the production and secretion of inflammatory mediators. Concurrently, Brodin's binding to Keap1 releases the transcription factor Nrf2 (Nuclear factor erythroid 2-related factor 2). Nrf2 subsequently translocates to the nucleus, where it upregulates the expression of enzymes that contribute to antioxidant capacity and cellular defense. This dual modulation of NF-kappaB and Nrf2 defines the drug's core action on inflammation and oxidative stress signaling.

The mechanism is extended through the drug's influence on the c-Myc/HIF-1alpha signaling axis and cytokine production ratios. This modulation alters the expression of immune regulatory factors, facilitating T-cell activity (via increased IL-2) and concurrently decreasing factors associated with immune suppression (via decreased IL-10). The resultant system-level physiological effect is a distinct modulation of cell-mediated immune responses and altered cytokine profiles.

Dosage and Administration Information

How Brodin is Used: Official Administration Guidelines

Brodin (Levofloxacin) is an anti-infective agent whose administration follows standardized clinical protocols to ensure proper use.


Official Routes, Forms, and Dosing

Brodin is approved for systemic and localized use, with the method of administration depending on the required pharmaceutical form.

Instruction Domain Standardized Administration Profile
Approved Routes Oral (tablets/solution), Intravenous (IV) (solution for infusion), and Topical (ophthalmic solution).
Standard Dosing Systemic doses typically range from 250 mg to 750 mg once daily, for durations ranging from 3 to 14 days (e.g., 750 mg for a 5-day course or 500 mg for a 7-day course).
Dosing Frequency The standard frequency for systemic administration is once daily (every 24 hours).

Administration Requirements and Adjustments

Proper use requires adherence to specific instructions regarding intake and adjustments, as outlined in standard clinical documentation:

  • Intake Timing: Oral Tablets can be taken with or without food. However, the Oral Solution must be taken 1 hour before or 2 hours after food.
  • IV Administration: The Solution for Infusion must be administered by slow intravenous infusion over a defined period (e.g., 60 minutes for 500 mg), and rapid bolus injection must be avoided.
  • Dose Adjustment: An adjustment to the dose or interval is required for adult patients with a Creatinine Clearance < 50 mL/min due to impaired kidney function.
  • Cation Restriction: Oral forms must be administered at least 2 hours before or 2 hours after products containing iron salts, zinc, or magnesium/aluminum (e.g., antacids) to prevent reduced absorption.

These administration guidelines dictate the standardized, procedural structure for the proper dispensing and intake of the medicine.

Recent Clinical Evidence

The Research Base for Brodin (Levofloxacin)

This section provides an overview of the types of research and clinical trials that form the foundation for Brodin's regulatory documentation, focusing on what was studied and what broad conclusions regulatory bodies rely on. This overview uses patient-friendly language to describe the research without providing individual predictions or clinical guidance.


Research Evidence in Acute Systemic Infections

Research for Brodin in acute systemic infections is primarily based on Randomized Controlled Trials (RCTs). For Community-Acquired Pneumonia (CAP), research explored outcomes related to both clinical response and microbiological endpoints. Findings describe patterns observed where the measured outcomes for both endpoints were similar to those reported for other common treatments. The variability in outcomes due to evolving antimicrobial resistance patterns is a documented area of concern.

For Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), research examined short-term symptom changes. Trials compared Brodin against alternative antibiotics, and research described patterns where the measured clinical outcomes were similar across the different treatment groups. For infections like Complicated Urinary Tract Infections (cUTI), studies monitored outcomes related to the microbiological eradication of the infecting bacteria and clinical resolution of symptoms.


Evidence for Prolonged or Specialty Use

For Chronic Bacterial Prostatitis, studies employed extended follow-up periods to monitor the status of the pathogen and changes in patient-reported outcomes. Findings describe patterns related to the status of the microbial endpoints at extended time points after the treatment interval.

The evidence for Inhalational Anthrax (Post-Exposure Prophylaxis) is based on efficacy studies in animal models (non-human primates). These animal studies monitored endpoints related to disease progression. The findings are linked to humans through separate Pharmacokinetic (PK) studies that describe the drug concentrations achieved in adults and children.


Evidence Gaps and Areas of Scientific Uncertainty

Official scientific literature acknowledges that the emergence of antimicrobial resistance is a constant factor that means results apply only to the current populations studied and research describes that continuous surveillance is a requirement. Follow-up durations were limited in many acute studies, and data for certain complex groups remain insufficient for conclusive findings.

Frequently Asked Questions (FAQ)

Common questions about Brodin (FAQ)


Q: Are there official warnings about taking Brodin with alcohol?

Regulatory documents generally advise caution regarding the use of alcohol during Brodin treatment. This is because the medication can cause central nervous system (CNS) side effects, such as dizziness or lightheadedness. Alcohol consumption may increase or worsen these CNS effects.

Q: Are there specific food items or drinks that should be avoided with Brodin?

According to official documents, Brodin tablets can be taken either with or without food. However, the oral solution form is required to be taken either one hour before or two hours after a meal. Aside from the mandatory separation from metal-containing products, no common food or drinks are specifically forbidden.

Q: Are there interactions with any over-the-counter cold and flu medications?

Official product information indicates that Brodin interacts with certain components commonly found in over-the-counter cold and flu medications. These components include nonsteroidal anti-inflammatory drugs (NSAIDs) and antacids, which contain metal cations. Information regarding these interactions is intended for patients to be aware of the potential for reduced absorption or increased side effects.

Q: Can Brodin be crushed or split if someone has trouble swallowing?

Official product information states that the oral tablets should be swallowed whole. Regulatory documents specify that the tablets are required to be swallowed whole and are not authorized to be crushed, split, or chewed. Altering the tablet form in this way may change how the medicine is absorbed into the body.

Q: Can Brodin be used for conditions not listed on the official label?

Regulatory documents outline the specific bacterial infections and patient populations for which Brodin has been officially approved and authorized for use. The information provided by government sources is limited only to these approved uses (indications).

Q: Can Brodin be taken with vitamin D or other basic vitamins?

Official information requires that Brodin be taken at least two hours before or two hours after products that contain metal cations. These cations include iron, zinc, calcium, and magnesium, which are common ingredients in many vitamins and mineral supplements. This time separation is required to ensure the antibiotic is properly absorbed.

Q: Does Brodin carry any specific warnings for individuals with a history of depression or anxiety?

Official warnings for Brodin include potential central nervous system (CNS) adverse reactions, such as anxiety, nervousness, and rare psychotic reactions. Regulatory documents advise caution for individuals who have a history of CNS disorders.

Q: Does Brodin have a boxed warning (black box warning) from the FDA?

Yes, the official FDA label includes a Boxed Warning that alerts patients and prescribers to the risk of serious side effects. These reactions, which can sometimes be long-lasting, include damage to tendons (tendon rupture), nerve damage (peripheral neuropathy), and certain central nervous system effects.

Q: Does Brodin have any known effects on liver function?

Official safety information indicates that Brodin can affect liver function. Increases in liver enzymes are classified as a common adverse reaction. In rare cases, severe liver injury, including cases of hepatitis, has been documented in official labeling.

Q: Does Brodin work differently for men versus women?

Studies reviewed by regulatory agencies generally state that no clinically relevant differences have been noted in the drug's action or measured effectiveness between male and female patients. The way the drug is processed by the body (pharmacokinetics) is considered similar across sexes.

Q: Does the evidence for Brodin cover all types of people or only specific groups?

Clinical trial evidence, as reviewed by regulatory bodies, primarily focused on specific systemic infections in the adult population. Official documents acknowledge that data for certain complex groups, such as children or patients with severe pre-existing conditions, may be limited or insufficient.

Q: Do regulatory agencies list Brodin as a high-risk medication?

While regulatory agencies do not use the specific term 'high-risk,' the official profile indicates that caution is required. This is demonstrated by the Boxed Warning for serious side effects and by the fact that the drug is reserved for certain uncomplicated infections only when no alternative treatment options exist.

Q: How quickly can I expect Brodin to start working?

Clinical studies track specific outcomes, such as time until clinical improvement is noted. For acute infections, evidence indicates that the therapeutic effect can often begin within the first few days of starting treatment.

Q: How is Brodin different from older treatments for the same condition?

Brodin is a synthetic, broad-spectrum antibiotic belonging to the Fluoroquinolone class, which distinguishes it from older categories of antibiotics. Its mechanism involves targeting key bacterial enzymes, such as DNA gyrase, which distinguishes it from certain older antibiotic categories.

Q: Is Brodin a medication that requires long-term use?

Brodin is primarily authorized for short-term treatment of acute bacterial infections, with most courses lasting between 3 and 14 days. However, for certain conditions, such as chronic bacterial prostatitis, official documents support the use of longer treatment durations.

Q: Is Brodin the same type of medicine as [similar drug name]?

Brodin's active ingredient, Levofloxacin, is classified as an antibiotic belonging to the Fluoroquinolone class. Structurally, it is defined as a specific chemical form (the S-enantiomer) of the older drug Ofloxacin, which is a key distinction noted in official documents.

Q: Is feeling [vague symptom, e.g., slightly tired] a known effect of Brodin?

Official safety information often lists general feelings like fatigue or asthenia (weakness) as potential side effects. These feelings may be accompanied by or related to other documented central nervous system effects, such as dizziness.

Q: Is there any information on Brodin's effect on mental clarity or memory?

Regulatory documents list adverse reactions related to the central nervous system, including anxiety, dizziness, and insomnia. Rare reports of confusion, hallucinations, or seizures are also documented, and these reactions may potentially impact concentration and mental clarity.

Q: Is a specific gene or blood test required before starting Brodin?

Testing of kidney function (creatinine clearance) is required in order to determine if a mandatory adjustment to the dose is necessary for adult patients with reduced kidney function.

Q: What does 'therapeutic window' mean in relation to Brodin?

The therapeutic window is a term used to describe the range of doses that can treat the infection effectively. Staying within this window means the dose is high enough to achieve the desired effect but not so high that it causes toxic or unacceptable adverse effects.

Q: What does the official product information say about Brodin and driving?

Official regulatory labeling advises caution regarding activities that require alertness, such as driving or operating machinery. This warning is due to the potential for the medication to cause central nervous system reactions, including dizziness, lightheadedness, or visual disturbances.

Q: What is the difference between Brodin and a generic version?

According to regulatory standards, a generic version must contain the identical active ingredient, Levofloxacin. The generic must also be shown to be pharmaceutically equivalent and bioequivalent, meaning it acts the same way in the body as the brand-name product.

Q: What is the meaning of the [specific safety term, e.g., 'contraindication'] related to Brodin?

A contraindication is a critical safety term defined in regulatory documents. It signifies a condition or factor that serves as a compelling reason to withhold the medication because its use in that circumstance is associated with a high and unacceptable risk of harm.

Q: What is the purpose of the inactive ingredients in the Brodin tablet/capsule?

Official product descriptions indicate that inactive ingredients are included in the formulation for specific purposes other than a therapeutic effect. They are used to stabilize the active ingredient, aid in its absorption within the body, or provide a recognizable color and shape to the tablet or capsule.

Q: What is the typical timeframe Brodin stays in the system?

Pharmacokinetic studies indicate that Brodin has an elimination half-life of approximately 6 to 8 hours in patients with normal kidney function. The half-life describes the typical time it takes for the drug concentration in the body to be reduced by half.

Q: What should I do if the side effects of Brodin feel too severe?

Official patient documents instruct that if any adverse reaction becomes severe, or if signs of a serious or rare reaction occur, immediate medical attention is the required course of action.

Q: What happens if I miss a time when I usually take Brodin?

Official patient instructions on a missed dose generally advise taking the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory instruction is to skip the missed dose and resume the normal schedule.

Q: Why does Brodin need to be taken consistently?

Consistent administration is necessary to maintain therapeutic drug concentrations in the body. This continuous level of medicine is required to effectively eliminate the bacteria causing the infection and to minimize the risk of developing antimicrobial resistance.

Q: Why do official documents mention that Brodin should not be stopped suddenly?

As Brodin is an antibiotic, regulatory sources emphasize the importance of completing the full course of treatment as prescribed. Stopping the medicine suddenly before the course is finished can fail to eliminate all the bacteria, potentially leading to treatment failure and contributing to antimicrobial resistance.

How should Brodin be stored and disposed of?

How to Store and Dispose of Brodin (Levofloxacin)

Official regulatory labeling dictates strict storage and disposal requirements for Brodin (Levofloxacin) to maintain product stability and safety.

Storage Conditions

Temperature & Protection: Brodin tablets, oral solutions, and infusion solutions must be stored at Controlled Room Temperature (20 C to 25 C). The product must be protected from light and liquid forms, including the ophthalmic solution and infusion, must be protected from freezing. Excessive heat must also be avoided.

Container: All forms must be kept in their original container and the container must remain tightly closed to protect from moisture.

Child Safety: All medicine must be stored out of the sight and reach of children.

️ Disposal Requirements

Any unused, unneeded, or expired Brodin must be thrown away. Patients are instructed to follow the official safe drug disposal guidelines provided by government health agencies, such as those from the FDA, and should consult a pharmacist about the best disposal method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Brodin found in:

A-Z Index: